Venous Thromboembolism

New Therapy Means Patients Can Be Treated at Home

Published in Blood Weekly, September 30th, 1996

The Health Protection Branch has approved a drug to treat blood clots in veins (venous thromboembolism), the most common preventable cause of death in hospital affecting more than 40,000 Canadians each year.

The anticoagulant drug, called innohep (tinzaparin) by Leo Laboratories Canada Ltd., belongs to a class of drugs called low molecular weight heparins that can significantly change the way patients with blood clots are managed.

"These new therapies are a real benefit for patients," said Dr. Graham Pineo, Calgary General Hospital. "The ability to receive treatment at home - instead of in a hospital bed hooked up to an intravenous unit - allows the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1996-09-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry